Document is current
Any future updates will be listed below
-
Authors
Brunner, Andrew M. https://orcid.org/0000-0002-2169-4115
Leitch, Heather A.
van de Loosdrecht, Arjan A.
Bonadies, Nicolas https://orcid.org/0000-0001-8761-2066
-
Funding
Funding for this research was provided by:
This review was funded by Bristol Myers Squibb
- License Information
-
More Information
Article History
Received: 23 August 2022
Revised: 30 November 2022
Accepted: 1 December 2022
First Online: 14 December 2022
Competing interests
: A.M.B. has received advisory board/research funding to institution from Acceleron Pharma, Agios, Alexion, Amgen, AstraZeneca, Celgene/BMS, Gilead, GSK, Janssen, Keros Therapeutics, Novartis, Taiho, and Takeda; and has received financial support for travel, consultancy honoraria, and research funding to institution from Pfizer. H.A.L. reports honoraria, advisory boards, and research funding from AbbVie, Alexion, AstraZeneca, BMS, Celgene, Janssen, Novartis, and Taiho. A.A.vdL. has received advisory board/research funding from Alexion, Amgen, Celgene/BMS, Novartis, Pfizer, and Roche. N.B. has received research funding to institution from Alexion, Astellas, Celgene/BMS, Novartis, Roche, Sandoz, Servier, and Takeda; financial support for travel from Amgen, Celgene/BMS, Gilead, Janssen, Novartis, and Roche; and consultancy honoraria from Janssen, Keros Therapeutics, and Novartis.
